A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Dees
E Claire
EC
Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.
Baker
Sharyn D
SD
O'Reilly
Seamus
S
Rudek
Michelle A
MA
Davidson
Susan B
SB
Aylesworth
Cheryl
C
Elza-Brown
Kathy
K
Carducci
Michael A
MA
Donehower
Ross C
RC
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D016879:Salvage Therapy; D019311:Staurosporine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D013997:Time Factors
D000970:Antineoplastic Agents; C054852:7-hydroxystaurosporine; D011493:Protein Kinase C; D019311:Staurosporine